Peking University Cancer Hospital, Department of Thoracic Oncology I, Deputy Chief Physician Specialties: Individualized and comprehensive treatment of thoracic solid tumors including lung cancer, thymic malignancies, and pleural mesothelioma, with extensive clinical experience. Professional Affiliations: - Standing Committee Member, Oncology Branch, China Ethnic Medicine Association - Standing Committee Member, Thoracic Precision Treatment Branch, China Geriatric Health Association - Standing Committee Member, Thoracic Precision Treatment Branch, Beijing Integrated Medicine Association - Standing Committee Member, Lung Cancer Professional Committee, Beijing Anti-Cancer Association - Member, Lung Cancer Immunotherapy Committee, Chinese Anti-Cancer Association Research: Principal Investigator of a general project funded by the National Health Commission: Study on the mechanisms related to the efficacy of immunotherapy in extensive-stage small-cell lung cancer. Representative Publications: - Li, J., et al., Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. BMC CANCER, 2020. 20(7931). - Li, J., et al., Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. JOURNAL OF THORACIC DISEASE, 2021. 13(3): p. 1813-1821. - Li, J., et al., Characteristics, survival, and risk factors of Chinese young lung cancer patients: the experience from two institutions. ONCOTARGET, 2017. 8(51): p. 89236-89244. - Li, J., et al., Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study. Translational Lung Cancer Research, Vol 14, No 7, July 2025. - Li, J., et al., High risk occupational exposure and family history were risk factors in young lung cancer in Chinese. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016. 9(12): p. 23650-23657.